FEMSelect (Formerly Pop Medical Solutions)
VerifiedThe developer the FDA cleared and CE Marked system for suturing ligaments of the pelvic floor as an approach to minimally-invasive Pelvic Organ Prolapse (POP) procedures.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$36—54m (Dealroom.co estimates Oct 2022.)
Tel Aviv-Yafo Tel Aviv District (HQ)
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 40 % | - | 29 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
* | $9.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Recent News about FEMSelect (Formerly Pop Medical Solutions)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.